# JUNS (Jupiter Neurosciences, Inc.) - SEC EDGAR Financial Statements

> Jupiter Neurosciences, Inc. reported $22K in revenue and a net loss of $14.14M for the fiscal year ended December 31, 2025, with a 80.6% gross margin and a -61068.3% operating margin.

- Canonical: https://convexityos.com/fundamentals/JUNS
- Markdown: https://convexityos.com/fundamentals/JUNS.md
- SEC CIK: 0001679628
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:11 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001679628&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | $22K | Dec 31, 2025 |
| Operating Income | FY 2025 | -$13.31M | -61068.3% margin |
| Net Income | FY 2025 | -$14.14M | -64853.4% net margin |
| Diluted EPS | FY 2025 | -$14.52 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $301K | Total debt: $225K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| **Revenue** | $22K | $0 | -- |
| Cost of Revenue | $4.2K | -- | -- |
| **Gross Profit** | $18K | -- | -- |
| Research & Development | $2.09M | $493K | $955K |
| Selling, General & Admin | $6.84M | -- | -- |
| Total Operating Expenses | $8.93M | $3.09M | $3.87M |
| **Operating Income** | -$8.91M | -$3.09M | -$3.87M |
| Interest Income | -- | $5.6K | $482 |
| Interest Expense | $66K | $248K | $219K |
| **Net Income** | -$8.64M | -$2.44M | -$4.78M |
| Basic EPS | -$18.80 | -$6.01 | -$13.53 |
| **Diluted EPS** | -$18.80 | -$6.01 | -$13.53 |
| Basic Shares Outstanding | 460.6K | 382.8K | 351.2K |
| Diluted Shares Outstanding | 460.6K | 382.8K | 351.2K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $14K | $24K | $19K | -- | -- | -- | $0 | -- |
| Cost of Revenue | $4.3K | $3.2K | $4.4K | -- | -- | -- | -- | -- |
| **Gross Profit** | $9.6K | $21K | $14K | -- | -- | -- | -- | -- |
| Research & Development | $3.89M | $600K | $411K | $44K | $817K | $759K | $467K | $201K |
| Selling, General & Admin | $1.91M | $2.16M | $1.57M | -- | -- | -- | -- | -- |
| Total Operating Expenses | $5.81M | $2.76M | $1.98M | $2.83M | $2.30M | $2.26M | $1.54M | $1.46M |
| **Operating Income** | -$5.80M | -$2.74M | -$1.96M | -$2.81M | -$2.30M | -$2.26M | -$1.54M | -$1.46M |
| Interest Income | $7.2K | $10K | $18K | -- | $10K | $13K | $10K | $5.4K |
| Interest Expense | $68K | $91K | $119K | $62K | $1.2K | $1.1K | $1.2K | $31K |
| **Net Income** | -$7.22M | -$2.27M | -$2.06M | -$2.58M | -$2.29M | -$2.25M | -$1.53M | -$1.53M |
| Basic EPS | -$7.42 | -$4.08 | -$4.51 | -- | -$5.04 | -$5.09 | -$3.76 | -- |
| **Diluted EPS** | -$7.42 | -$4.08 | -$4.51 | -- | -$5.04 | -$5.09 | -$3.76 | -- |
| Basic Shares Outstanding | 973.6K | 557.6K | 468.9K | -- | 453.9K | 442.4K | 440.3K | -- |
| Diluted Shares Outstanding | 973.6K | 557.6K | 468.9K | -- | 453.9K | 442.4K | 440.3K | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $3.79M | $3.77M | $28K |
| **Cash & Short-Term Investments** | $3.79M | $3.77M | $28K |
| Accounts Receivable, Net | $2.6K | -- | -- |
| Inventory | $160K | -- | -- |
| Other Current Assets | $107K | $114K | $261 |
| **Total Current Assets** | $4.82M | $4.65M | $29K |
| Other Non-Current Assets | $3.8K | $3.8K | $3.8K |
| **Total Non-Current Assets** | $739K | $1.55M | $120K |
| **Total Assets** | $5.56M | $6.20M | $149K |
| Accounts Payable | $131K | $279K | $189K |
| Deferred Revenue (Current) | $735 | -- | -- |
| **Total Current Liabilities** | $7.40M | $2.01M | $5.77M |
| **Total Non-Current Liabilities** | $0 | $21K | $178K |
| **Total Liabilities** | $7.40M | $2.03M | $5.95M |
| **Total Debt (incl. Leases)** | $21K | $71K | $120K |
| Common Stock | $46 | $3.3K | $2.7K |
| Retained Earnings | -$34.67M | -$26.02M | -$23.58M |
| **Total Stockholders' Equity** | -$1.83M | $4.17M | -$5.80M |
| Total Equity | -$1.83M | $4.17M | -$5.80M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $301K | $1.52M | $2.36M | $3.79M | $724K | $1.88M | $2.71M | $3.77M |
| **Cash & Short-Term Investments** | $301K | $1.52M | $2.36M | $3.79M | $724K | $1.88M | $2.71M | $3.77M |
| Accounts Receivable, Net | -- | $10K | -- | $2.6K | -- | -- | -- | -- |
| Inventory | $131K | $135K | $148K | $160K | -- | -- | -- | -- |
| Other Current Assets | $60K | $115K | $133K | $107K | $142K | $174K | $138K | $114K |
| **Total Current Assets** | $1.26M | $2.55M | $3.41M | $4.82M | $1.63M | $2.82M | $3.61M | $4.65M |
| Other Non-Current Assets | $15K | $618K | $3.8K | $3.8K | $3.8K | $3.8K | $3.8K | $3.8K |
| **Total Non-Current Assets** | $365K | $1.17M | $538K | $739K | $944K | $1.15M | $1.35M | $1.55M |
| **Total Assets** | $1.62M | $3.72M | $3.95M | $5.56M | $2.58M | $3.97M | $4.96M | $6.20M |
| Accounts Payable | $269K | $360K | $92K | $131K | $367K | $465K | $158K | $279K |
| Deferred Revenue (Current) | -- | $859 | -- | $735 | $6.7K | -- | -- | -- |
| **Total Current Liabilities** | $2.59M | $3.88M | $6.73M | $7.40M | $2.52M | $2.63M | $1.89M | $2.01M |
| **Total Non-Current Liabilities** | $198K | $205K | $0 | $0 | $0 | $0 | $8.5K | $21K |
| **Total Liabilities** | $2.79M | $4.08M | $6.73M | $7.40M | $2.52M | $2.63M | $1.90M | $2.03M |
| **Total Debt (incl. Leases)** | $225K | $221K | $8.5K | $21K | $34K | $46K | $59K | $71K |
| Common Stock | $132 | $66 | $3.6K | $46 | $3.4K | $3.5K | $3.3K | $3.3K |
| Retained Earnings | -$46.23M | -$39.00M | -$36.73M | -$34.67M | -$32.09M | -$29.80M | -$27.55M | -$26.02M |
| **Total Stockholders' Equity** | -$1.16M | -$366K | -$2.78M | -$1.83M | $57K | $1.34M | $3.06M | $4.17M |
| Total Equity | -$1.16M | -$366K | -$2.78M | -$1.83M | $57K | $1.34M | $3.06M | $4.17M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$8.64M | -$2.44M | -$4.78M |
| Stock-Based Compensation | $2.42M | $1.84M | $1.20M |
| Change in Receivables | -$2.6K | -- | -- |
| Change in Inventory | -$160K | -- | -- |
| **Operating Cash Flow** | -$5.41M | -$3.91M | -$481K |
| Common Stock Issued | -- | $150K | $55K |
| **Financing Cash Flow** | $5.43M | $7.65M | $445K |
| **Net Change in Cash** | $20K | $3.74M | -$36K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$7.22M | -$2.27M | -$2.06M | -$2.58M | -$2.29M | -$2.25M | -$1.53M | -$1.53M |
| Stock-Based Compensation | $552K | $491K | $501K | $463K | $1.07M | $462K | $421K | $1.01M |
| Change in Receivables | $10K | -$10K | $2.6K | -- | -- | -- | -- | -- |
| Change in Inventory | $4.3K | $13K | $12K | -- | -- | -- | -- | -- |
| **Operating Cash Flow** | -$2.72M | -$2.29M | -$1.43M | -$2.37M | -$1.15M | -$828K | -$1.06M | -$3.70M |
| **Financing Cash Flow** | $1.50M | $1.45M | $5.5K | -- | -- | -- | -- | $7.47M |
| **Net Change in Cash** | -$1.22M | -$841K | -$1.43M | $3.07M | -$1.15M | -$828K | -$1.06M | $3.77M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| **Gross Margin** | 80.6% | -- | -- |
| **Operating Margin** | -40873.2% | -- | -- |
| **Net Profit Margin** | -39662.8% | -- | -- |
| Return on Equity (ROE) | -- | -58.5% | -- |
| Return on Assets (ROA) | -155.4% | -39.3% | -3219.3% |
| Current Ratio | 0.65x | 2.31x | 0.00x |
| Quick Ratio | 0.63x | 1.88x | 0.00x |
| Debt to Equity | -- | 0.02x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -- | -- | -- | -- | -13232.1% | -440.3% | -108.8% | -58.5% |
| Return on Assets (ROA) | -870.9% | -247.4% | -232.4% | -155.4% | -294.9% | -148.7% | -67.2% | -39.3% |
| Current Ratio | 0.49x | 0.66x | 0.51x | 0.65x | 0.65x | 1.07x | 1.91x | 2.31x |
| Quick Ratio | 0.44x | 0.62x | 0.48x | 0.63x | 0.29x | 0.71x | 1.43x | 1.88x |
| Debt to Equity | -- | -- | -- | -- | 0.59x | 0.03x | 0.02x | 0.02x |
| **Net Income Growth (YoY)** | -- | -- | -- | -- | -- | -819.5% | -- | -- |
| EPS Growth (YoY) | -- | -- | -- | -- | -- | -777.0% | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
